BioCentury
ARTICLE | Clinical News

Seciera: Phase IIb/III data

November 23, 2015 8:00 AM UTC

A double-blind, U.S. Phase IIb/III trial in 455 patients with dry eye disease showed that twice-daily 0.05% and 0.09% Seciera each met the co-primary endpoint of improving conjunctival lissamine green...